Also known as: RVO
Retinal vein occlusion is a vascular eye disease caused by blockage of retinal venous outflow, leading to retinal hemorrhage, edema, and vision loss. Major subtypes are branch and central retinal vein occlusion.
The FDA approved updated labeling for Vabysmo to allow extended treatment of macular edema following retinal vein occlusion beyond six months. The label update removes the prior 6-month restriction and retains monthly 6 mg intravitreal dosing.
The FDA approved an updated Vabysmo label for macular edema following retinal vein occlusion beyond six months. The decision extends treatment based on data showing visual acuity gains and central subfield thickness reductions maintained through week 72.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
The FDA has approved an expanded label for Sandoz's aflibercept biosimilar Enzeevu to include multiple retinal indications beyond its original approval for neovascular age-related macular degeneration. The product is expected to launch in the US in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06439576 |
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) |
ACTIVE_NOT_RECRUITING | |
| NCT03680794 |
Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies |
RECRUITING | NA |
| NCT01496625 |
National Eye Institute Biorepository for Retinal Diseases |
RECRUITING |
